Navigation Links
Human Pheromone Sciences Announces First Quarter Results
Date:5/14/2009

Current Period Results Impacted by Downturn in Worldwide Beauty Markets

SAN JOSE, Calif., May 14 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or the "Company") today announced results for the first quarter ended March 31, 2009. Net revenues of $165,000 represented a 38% decrease from the revenues of $266,000 in the prior year period, and resulted in a net loss of $181,000 ($0.04 per share) as compared with net loss of $63,000 ($0.02 per share) for the same period of 2008. At March 31, 2009, the Company reflected cash balances of $664,000 compared with $907,000 in cash at December 31, 2008, a $243,000 reduction in the quarter. There was no bank indebtedness at either period.

According to a Company spokesperson, "the revenue and cash declines were in line with the Company's internal forecasts, reflecting the extremely difficult overall adverse economic climate and the significant downturn in the worldwide Fragrance and Beauty Markets. We had anticipated the reduction of revenues on sales to our once largest fragrance and beauty-based company, and, as such, embarked upon a program to expand other potential markets for the use of our patented technology in other consumer product arenas. Some of the shortfall in the basic beauty area was offset by supply and royalty revenues received under our licensing agreement with Schwarzkopf & Henkel in the worldwide hair care and personal product markets. Pheromone purchases by our two primary licensees, increased by 79%, in anticipation of a new product launch in May 2009 by one of these companies. While the selling price of the pheromones is quite low compared to that of prior licensees, our newer agreements provide for royalties on licensee sales of products containing our patented technology. As such, we would anticipate an increase in royalty income in subsequent periods this year."

"Generating additional revenues under new licensing agreements will not only grow our business, but will reduce the effect of erratic purchasing patterns by one major licensee. In addition, while the Company is focusing on reducing expenditures, we continue to invest in maintaining our current patents and seeking such protection for our newest technology on a worldwide basis," the spokesperson indicated.

Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at www.erox.com.

The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-K for the year ended December 31, 2008, and Form 10-Q for the quarter ended March 31, 2009, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.

                                 Tables follow



                          HUMAN PHEROMONE SCIENCES, INC.

                            Condensed Balance Sheets
                             (Dollars in thousands)

                                          March 31,             December 31,
                                            2009                    2008
                                            ----                    ----
                                         (Unaudited)
    Assets

    Cash and cash equivalents                   $664                    $907
    Accounts receivable                           61                      52
    Inventories, net                              51                      39
    Other current assets                          34                      58
    Property and equipment, net                    2                       2
                                         -----------             -----------
    Total                                       $812                  $1,058
                                         ===========             ===========

    Liabilities and shareholders' deficit

    Accounts payable                             $54                     $19
    Other current liabilities                    103                     131
    Deferred income - current                    270                     297
    Deferred income - non-current                265                     324
    Common stock                              21,056                  21,043
    Accumulated deficit                      (20,936)                (20,756)
                                         -----------             -----------
    Total                                       $812                  $1,058
                                         ===========             ===========



                          HUMAN PHEROMONE SCIENCES, INC.

                        Condensed Statements of Operations
                                   (Unaudited)
                   (Dollars in thousands, except per-share data)

                                            Three months ended March 31,
                                               2009               2008
                                              ------             ------

    Net revenues                                $165               $266
    Cost of goods sold                            65                 81
    Research and development                      25                 14
    Selling, general and administrative          257                244
                                              ------             ------

    Income (loss) from operations               (182)               (73)

    Other income                                   1                 11

    Provision for income taxes                     -                  1
                                              ------             ------

    Net income (loss)                          $(181)              $(63)
                                              ======             ======


    Income (loss) per share, basic            $(0.04)            $(0.02)
                                              ======             ======

    Income (loss) per share, fully diluted    $(0.04)            $(0.02)
                                              ======             ======

    Weighted average common shares
     Outstanding - Basic                       4,152              4,152
                                              ======             ======
    Weighted average common shares
     Outstanding - Fully diluted               4,152              4,152
                                              ======             ======

    Net income (loss) per share is based on the weighted average number of
    common shares and common equivalents outstanding during each period.
    Certain common stock equivalents are excluded when their effect would be
    anti-dilutive.


'/>"/>
SOURCE Human Pheromone Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Embryonic Stem Cells Repair Human Heart
2. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
3. Human Papilloma Virus vaccines may decrease chances of oral cancer
4. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
5. MassMutual Promotes Debra Palermino to Senior Vice President of Human Resources
6. Toddler Study Proves Humans Outsmart Apes
7. Human C-reactive protein regulates myeloma tumor cell growth and survival
8. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. New class of RNA molecules may be important in human cancer
11. The Humana Foundation and Libraries for the Future Launch Health Literacy Pilot in Atlanta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners of America Pain ... an interventional pain management physician. He brings a wealth of pain management experience ... and significant experience in spinal cord stimulation for chronic pain. , Dr. Ahmed ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions ... definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation ...
(Date:8/18/2017)... ... ... The Dawn Johnson Insurance Group, a Missouri-based insurance and financial planning firm ... for efforts to educate the local population on cancer realities while attracting donations to ... , Each day in America, roughly 4,600 new cases of cancer are diagnosed and ...
(Date:8/18/2017)... Saint John, IN (PRWEB) , ... August 18, 2017 , ... ... services to communities in northwest Indiana, is campaigning in support of Campagna Academy in ... Formerly referred to as the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a ...
(Date:8/18/2017)... ... 18, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... on false teachings pertaining to the mother of the Savior whom the world calls “Mother ... different picture of the role of this historical woman. , “The world bows, kisses ...
Breaking Medicine News(10 mins):
(Date:8/11/2017)... CAESAREA, Israel , Aug. 11, 2017 ... company with mobile health and big data solutions, today ... results on Monday, August 14 and host a conference ... second quarter 2017 operating and financial results and its ... call will be hosted by Erez Raphael , ...
(Date:8/7/2017)... Insightin Health, provider of data-driven decision-making ... announced the selection of Michael Wood ... as of February 2017. In this role, Wood will ... our clients. Wood brings with him more than ... analytics within the healthcare industry. Wood formerly served ...
(Date:8/7/2017)... Aug. 7, 2017  Endo International plc (NASDAQ: ... to resolve virtually all known U.S. mesh product liability ... resolve the known remaining U.S. claims at reasonable values. ... in the fourth quarter of 2017 and continuing through ... second quarter 2017 results, the Company intends to increase ...
Breaking Medicine Technology: